Showing results 2 to 4 of 4
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
KEYNOTE-122: Phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma Proceeding/Conference:Annals of Oncology | 2016 | ||
KEYNOTE-495/KeyImPaCT: Interim Analysis of a Randomized, Biomarker-Directed, ProgramsPhase 2 Trial of Pembrolizumab-Based Combination Therapy for Non–Small Cell Lung Cancer Proceeding/Conference:The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021) | 2021 | ||
Pembrolizumab (MK-3475) vs Standard of Care Chemotherapy in Platinum Pretreated, Recurrent or Metastatic Nasopharyngeal Cancer: the Phase 2 Keynote-122 Study Proceeding/Conference:AHNS 9th International Conference of Head and Neck Cancer | 2016 |